Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
COYA
Upturn stock ratingUpturn stock rating

Coya Therapeutics, Inc. Common Stock (COYA)

Upturn stock ratingUpturn stock rating
$5.75
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: COYA (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

5 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $16.75

1 Year Target Price $16.75

Analysts Price Target For last 52 week
$16.75Target price
Low$4.65
Current$5.75
high$10.24

Analysis of Past Performance

Type Stock
Historic Profit -27.43%
Avg. Invested days 35
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 97.84M USD
Price to earnings Ratio -
1Y Target Price 16.75
Price to earnings Ratio -
1Y Target Price 16.75
Volume (30-day avg) 5
Beta 0.21
52 Weeks Range 4.65 - 10.24
Updated Date 06/29/2025
52 Weeks Range 4.65 - 10.24
Updated Date 06/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.07

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -2976.89%

Management Effectiveness

Return on Assets (TTM) -32.06%
Return on Equity (TTM) -52.11%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 62310614
Price to Sales(TTM) 26.55
Enterprise Value 62310614
Price to Sales(TTM) 26.55
Enterprise Value to Revenue 16.91
Enterprise Value to EBITDA -6.21
Shares Outstanding 16725000
Shares Floating 12571345
Shares Outstanding 16725000
Shares Floating 12571345
Percent Insiders 7.02
Percent Institutions 28.07

Analyst Ratings

Rating 3
Target Price 16.75
Buy 1
Strong Buy 4
Buy 1
Strong Buy 4
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Coya Therapeutics, Inc. Common Stock

stock logo

Company Overview

overview logo History and Background

Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing and commercializing innovative therapies for neurodegenerative diseases, with an emphasis on regulatory T cells (Tregs). Founded to address unmet needs in these areas, Coya has built a platform centered on Treg biology.

business area logo Core Business Areas

  • Treg-based Therapies: Focuses on developing therapies based on the immunomodulatory properties of Tregs for the treatment of neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD).
  • Pipeline Development: Engages in preclinical and clinical research to expand its pipeline of Treg-modulating therapies targeting various neurodegenerative and autoimmune diseases.

leadership logo Leadership and Structure

Coya Therapeutics is led by a management team with experience in immunology and drug development. The organizational structure includes research, clinical development, and business operations departments.

Top Products and Market Share

overview logo Key Offerings

  • COYA 101: An autologous Treg cell therapy being investigated for the treatment of ALS. The market share and revenue from this product is not available yet as the product is in clinical trials. Competitors include Biogen (Tofersen), Amylyx Pharmaceuticals (Relyvrio) and numerous other companies pursuing ALS treatments.
  • COYA 206: A biologic product designed to enhance Treg function, currently in preclinical development targeting neurodegenerative diseases. Competitors for this unreleased product are varied and highly dependent on the final indication.

Market Dynamics

industry overview logo Industry Overview

The biotechnology industry focused on neurodegenerative diseases is characterized by high unmet needs and significant research activity. The market is competitive with numerous companies developing novel therapies.

Positioning

Coya Therapeutics is positioned as a company specializing in Treg-based therapies for neurodegenerative diseases. Its competitive advantage lies in its focus on Treg biology and its potential to address the underlying immune dysfunction in these conditions.

Total Addressable Market (TAM)

The TAM for ALS and other neurodegenerative diseases is significant, projected to reach billions of dollars. Coya's position within this TAM is dependent on the success of its clinical trials and subsequent commercialization efforts.

Upturn SWOT Analysis

Strengths

  • Proprietary Treg platform
  • Focus on neurodegenerative diseases with high unmet needs
  • Experienced management team
  • Promising early clinical data

Weaknesses

  • Limited financial resources
  • Dependence on clinical trial success
  • Relatively small company size
  • Single therapeutic focus

Opportunities

  • Partnerships with larger pharmaceutical companies
  • Expansion of pipeline to other autoimmune diseases
  • Positive clinical trial results leading to accelerated approval
  • Increasing awareness of Treg-based therapies

Threats

  • Clinical trial failures
  • Competition from established pharmaceutical companies
  • Regulatory hurdles
  • Funding challenges

Competitors and Market Share

competitor logo Key Competitors

  • BIIB
  • AMLY

Competitive Landscape

Coya Therapeutics faces competition from established pharmaceutical companies with greater resources and broader pipelines. Its competitive advantage lies in its specialized Treg platform.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is characterized by preclinical and early clinical development activities. Growth is tied to achieving clinical milestones.

Future Projections: Future growth depends on successful clinical trials, regulatory approvals, and commercialization. Analyst projections, if available, are highly speculative.

Recent Initiatives: Recent initiatives include advancing clinical trials for COYA 101 and progressing preclinical development for COYA 206.

Summary

Coya Therapeutics is a clinical-stage biotech focused on Treg therapies for neurodegenerative diseases. Its success hinges on positive clinical trial outcomes. The company's small size and limited resources pose challenges, while successful trials could lead to significant opportunities. Investors should closely monitor clinical trial results and financial runway.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings
  • ClinicalTrials.gov
  • Analyst Reports (where available)

Disclaimers:

This analysis is for informational purposes only and does not constitute financial advice. Data is based on publicly available information and may not be entirely accurate or complete. Investment decisions should be based on individual research and consultation with a qualified financial advisor.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Coya Therapeutics, Inc. Common Stock

Exchange NASDAQ
Headquaters Houston, TX, United States
IPO Launch date 2022-12-29
CEO & Director Dr. Arun Swaminathan Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 8
Full time employees 8

Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary therapies to enhance the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages in Phase 2 trial for use in the treatment of amyotrophic lateral sclerosis, as well as frontotemporal dementia, Alzheimer's disease (AD), and Parkinson's disease. In addition, the company's pre-clinical product candidates include COYA 301, a low-dose interleukin 2 product candidate to treat AD; COYA 303, an investigational biologic combination of COYA 301 and a glucagon-like-peptide-1 receptor agonist for the treatment of inflammatory diseases; COYA 201, an antigen directed Treg-derived exosome product candidate to treat neurodegenerative, autoimmune, and metabolic diseases; COYA 206, an antigen directed Treg-derived exosome product candidate; and COYA 101. It has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. Coya Therapeutics, Inc. was founded in 2020 and is headquartered in Houston, Texas.